An observational study in Arteriovenous Malformation and Bleeding, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-08-12.
Sponsored by Beijing Tiantan Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Intracranial Arteriovenous Malformations with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Arteriovenous Malformations · China.
Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, this one is the only one that started in 2025, is one of 7 observational ones, and was the 11th registered.
43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.
Browse Intracranial Arteriovenous Malformations studies →4 of the 13 studies in Intracranial Arteriovenous Malformations with a site in China are open now. Recruiting first, the newest first:
Duan Chuanzhi · Sites in China
Zhuhai Tonbridge Medical Tech. Co., Ltd. · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 13 Intracranial Arteriovenous Malformations studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 162 is above the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.
Median enrollment 460 across the 6 interventional studies, 300 across the 7 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
Beijing Tiantan Hospital has 6 studies filed under Intracranial Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
1 of the studies in Intracranial Arteriovenous Malformations with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118631Beijing Tiantan HospitalClinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cerebral arteriovenous malformation (AVM) is the leading cause of brain hemorrhage in young adults, characterized by sudden onset and rapid progression. The hybrid neurosurgical operating room is a diagnostic and therapeutic platform that integrates neurointervention and microneurosurgery, offering advantages such as one-stop rapid treatment and multimodal therapeutic approaches.
This study aims to focus on patients with acute cerebral AVM-related hemorrhage through a multicenter, prospective, registry-based research approach. In the hybrid neurosurgical operating room, emergency cerebral angiography, neurointerventional embolization, microsurgical resection of the vascular malformation, or minimally invasive hematoma evacuation will be performed to explore the indications and advantages of the hybrid neurosurgical operating platform in emergency AVM hemorrhage management. The study seeks to establish standardized diagnostic and treatment protocols and operational workflows for emergency AVM hemorrhage management in the hybrid operating room. Through continuous quality improvement, the study aims to further reduce patient morbidity and mortality.
This research will not only enhance the diagnostic and therapeutic level of cerebral AVM-related hemorrhage and improve patient outcomes but also effectively reduce medical costs and societal burdens.
43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.
This study's planned enrollment of 162 is above the median of 140 across 25 observational studies indexed under Intracranial Arteriovenous Malformations.
Browse Intracranial Arteriovenous Malformations studies →Beijing Tiantan Hospital is the lead sponsor of 494 studies on the registry; 298 are open to participants now.
Compared within Intracranial Arteriovenous Malformations, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Arteriovenous Malformations. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Patients with mergency cerebral arteriovenous malformation bleeding
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
After patients were enrolled, they were admitted to the hybrid operating room for DSA to confirm the diagnosis. If the patient meets the surgical indications, one-stop treatment with composite surgery will be performed. During the operation, the treatment plan is determined based on the characteristics of the malformation group, including simple embolization, partial embolization, auxiliary embolization for arteriovenous malformation resection, and the target area and proportion of embolization. For those who need craniotomy, the hematoma is removed during the operation and the brain arteriovenous malformation is removed under a microscope. Intraoperative ultrasound assists in locating the location, boundaries and residue of the malformation. Head DSA was reviewed immediately after surgery. Further clarify whether the lesions are completely removed. If the lesion remains, immediate surgical treatment and subsequent DSA review will be perfor
Neurological outcomes
modified rankin scale (mRS), The scale runs from 0-6. Higher scores mean a worse outcome
Time frame: 2 weeks, 3 months, 6 months after surgery
surgical information
Time frame: pre-surgery, during the surgery, perioperatively immediately after the surgery
Complications
Time frame: 2 weeks, 3 months, 6 months after surgery
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 31 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriovenous Malformations →